… pharmaceutical companies leading the way in the development of innovative treatments … pipeline of next-generation drugs targeting novel pathways … 6 inhibitors (such as Actemra), and JAK inhibitors (such … by limited access to medications in developing countries …

… (n = 1) of patients. Tocilizumab (Actemra) was used in 34% (n … -cell therapy has revolutionized the treatment paradigm for patients with B … (n = 4), receipt of alternative treatment (n = 2), and missing reason …

… out more on FDA-approved GCA drugs @ Giant-Cell Arteritis Treatment Options Productive … ;Kiniksa Pharmaceuticals (Mavrilimumab), among others, have initiated clinical trials that investigate new treatment …

… deal with Celltrion to produce drug substances for two clinical-stage … launch of Avtozma, Celltrion’s Actemra (tocilizumab) biosimilar used to treat … company to secure U.S. FDA current good manufacturing practice (cGMP …

… /tolerability. Baseline Characteristics and Treatment Discontinuation Among all enrolled patients … of patients. TEAEs led to trial drug discontinuation or dose delay in … experiencing this AE received tocilizumab (Actemra). Most CRS events occurred during …

… ,” Kerr said. Any-grade treatment-emergent AEs (TEAEs) were … 3% were related to the drug. One TEAE was grade … Interventions for CRS included tocilizumab (Actemra; 19%), corticosteroids (8%), tocilizumab … plus pola-R-CHP treatment expands CD8-positive effector …

… professor of medicine, hematology and medical oncology at … antibody, an immunomodulatory drug (IMiD), and a … Overall supportive measures included tocilizumab (Actemra; 77%), dexamethasone (73%), … 1%). The most common treatment-emergent adverse effects (TEAEs …

… phase 1b TRIMM-3 trial (NCT05338775) presented during … (54.5%) with tocilizumab (Actemra; 34.1%), followed by … /2 MonumenTAL-1 trial (NCT03399799; NCT04634552).3 Infections … -fda-approves-talveytm-talquetamab-tgvs-first-class-bispecific-therapy-treatment …

… received 1 prior line of treatment (n = 10), the ORR … have 1 prior line of treatment. The trial’s primary end point … response, as well as pharmacokinetics. Treatment-emergent adverse events (TEAEs) … measure for CRS was tocilizumab (Actemra), given to 76% at …

… the phase 3 ZUMA-7 trial (NCT03391466), regardless of age, … consistent with the ZUMA-7 trial, [despite the fact that] … (Actemra; 70%), corticosteroids (68%), or anakinra (Kineret; 16%) as treatment for … limited due to the trial’s differing assessment timeline …